论文部分内容阅读
马法兰(melphalan)常用来治疗各种肿瘤,包括多发性骨髓病,真性红细胞增多症和乳癌,在治疗这些肿瘤过程中常常并发骨髓抑制。作者于1968～1976年间使用马法兰治疗33例新近诊断的慢粒白血病患者,获得较满意的疗效。马法兰的治疗剂量和方法如下:诱导治疗应用4～12毫克/日(根据白细胞数而定),5～7天后逐渐减至维持量。多数患者的治疗量为2～4毫克/日,有一例每周只用3次,每次2毫克。白细胞降至5,000以下时停药,直至白细胞回升至正常以上为止。在诱导治疗或病情复发治疗期间加用别嘌呤醇,至维持治疗期停止。本文33例.男19例,女14例。所有病例的白细胞数均大于30,000,最高为1,135,0003例外周血原始细胞大于10%,13例为2～10%。贫血患者(血红蛋白男少于14克,女少于12克)22例。2例血小板数少于150.000,7例大于600,000。26例有自觉症状。24例脾肿大,其中17例大于肋下3厘米。治疗后5例的自
Melphalan is commonly used to treat a variety of tumors, including multiple myelopathy, polycythemia vera and breast cancer, often with concurrent myelosuppression in the treatment of these tumors. The authors used melphalan in the treatment of 33 newly diagnosed CML patients between 1968 and 1976 and achieved satisfactory results. The therapeutic dose and method of melphalan are as follows: The induction therapy is applied to 4 to 12 mg / day (based on the number of leukocytes) and gradually reduced to the maintenance dose after 5 to 7 days. The treatment of most patients is 2 ~ 4 mg / day, one case only 3 times a week, each 2 mg. Leukocytes dropped to 5,000 when the withdrawal until the white blood cells returned to normal above. Allopurinol was added during induction or relapse treatment until the maintenance phase of treatment was stopped. This article 33 cases, 19 males and 14 females. The number of white blood cells in all cases was greater than 30,000, with a maximum of 1,135,0003 peripheral blood blasts more than 10% and 13 of 2 to 10%. Anemia patients (hemoglobin less than 14 grams, less than 12 grams of women) in 22 cases. 2 cases of platelet count less than 150.000, 7 cases more than 600,000.26 cases of symptoms. 24 cases of splenomegaly, of which 17 cases greater than the ribs 3 cm. 5 cases after treatment since